Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Locking out hepatitis C

Nature Medicine volume 17, pages 542–544 (2011)Cite this article

Subjects

Hepatitis C virus puts about 130 million people worldwide at risk for severe liver disease, but no vaccine or broadly effective therapy yet exists. A new study identifies receptor tyrosine kinases as host factors required for hepatitis C virus entry—potentially opening the door for new antiviral strategies (pages 589–595).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Role of RTKs in HCV entry pathway and their potential as therapeutic targets.

Marina Corral

References

  1. Scarselli, E. et al. EMBO J. 21, 5017–5025 (2002).

    Article  CAS  Google Scholar 

  2. Pileri, P. et al. Science. 282, 938–941 (1998).

    Article  CAS  Google Scholar 

  3. Evans, M.J. et al. Nature 446, 801–805 (2007).

    Article  CAS  Google Scholar 

  4. Ploss, A. et al. Nature 457, 882–886 (2009).

    Article  CAS  Google Scholar 

  5. Lupberger, J. et al. Nat. Med. 17, 589–595 (2011).

    Article  CAS  Google Scholar 

  6. Verna, E.C. & Brown, R.S. Jr. Clin. Liver Dis. 12, 637–659 (2008).

    Article  Google Scholar 

  7. Eierhoff, T., Hrincius, E.R., Rescher, U., Ludwig, S. & Ehrhardt, C. PLoS Pathog. 6, e1001099 (2010).

    Article  Google Scholar 

  8. Chung, Y.H. et al. Cancer 89, 977–982 (2000).

    Article  CAS  Google Scholar 

  9. Duong, F.H., Christen, V., Lin, S. & Heim, M.H. Hepatology 51, 741–751 (2010).

    CAS  PubMed  Google Scholar 

  10. Vermehren, J. & Sarrazin, C. Clin. Microbiol. Infect. 17, 122–134 (2011).

    Article  CAS  Google Scholar 

  11. Guedj, J., Rong, L., Dahari, H. & Perelson, A.S. J. Viral Hepat. 17, 825–833 (2010).

    Article  CAS  Google Scholar 

  12. Fofana, I. et al. Gastroenterology 139, 953–964 (2010).

    Article  CAS  Google Scholar 

  13. Syder, A.J. et al. J. Hepatol. 54, 48–55 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gisa Gerold and Charles M. Rice are at the Center for the Study of Hepatitis C, Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.,

    Gisa Gerold & Charles M Rice

Authors
  1. Gisa Gerold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles M Rice
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Gisa Gerold or Charles M Rice.

Ethics declarations

Competing interests

C.M.R. is a member of the Scientific Advisory Board of iTherX, a company with a candidate hepatitis C virus entry inhibitor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gerold, G., Rice, C. Locking out hepatitis C. Nat Med 17, 542–544 (2011). https://doi.org/10.1038/nm0511-542

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0511-542

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research